Dec 04, 2025 4:05pm EST Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Dec 03, 2025 7:34am EST Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
Nov 03, 2025 8:29am EST Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
Aug 26, 2025 7:30am EDT Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September
Jul 29, 2025 7:35am EDT Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy
Jul 18, 2025 4:15pm EDT Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
Mar 18, 2025 7:30am EDT Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
Mar 13, 2025 7:30am EDT Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
